Abstract
Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody (MoAb) rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse with the original disease. A better understanding of the mechanism of rituximab resistance has led to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 MoAbs and explains new strategies to overcome resistance.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibody Specificity
-
Antibody-Dependent Cell Cytotoxicity
-
Antigens, CD20 / drug effects*
-
Antigens, CD20 / immunology
-
Apoptosis / drug effects
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology
-
Complement Activation
-
Drug Delivery Systems
-
Drug Resistance
-
Humans
-
Recombinant Fusion Proteins / immunology
-
Recombinant Fusion Proteins / therapeutic use
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
PRO131921 monoclonal antibody
-
Recombinant Fusion Proteins
-
TRU-015 protein
-
Rituximab
-
ocrelizumab
-
veltuzumab
-
ofatumumab
-
ocaratuzumab
-
obinutuzumab